FTC's proposed order would cap insulin at $25, $50 or $75 out of pocket for CVS Caremark plans

The Federal Trade Commission has proposed a consent order that would cap what patients pay out of pocket for insulin under plans managed by CVS Caremark, one of the largest pharmacy-benefit managers in the country, at $25, $50 or $75 per fill [1]. The order, published August 5, also names Zinc, the rebate-negotiating unit tied to Caremark, and would require negotiated rebates to be passed through to patients at the point of sale [1].

Pharmacy-benefit managers sit between insurers, drug manufacturers and pharmacies, negotiating the rebates that shape what a plan pays and, indirectly, what a patient owes at the counter. The FTC has argued that this rebate system can steer patients toward higher-list-price insulins, because the rebates flow to middlemen rather than to the person filling the prescription. Passing rebates through at the point of sale is the mechanism the proposed order uses to reverse that incentive [1].

The three ceilings, $25, $50 and $75, set a maximum a patient would owe per insulin fill under a covered Caremark plan [1]. What distinguishes the three, whether by insulin type, plan design or supply length, is not spelled out in the document text available for this writeup, so the piece states the caps without assigning a meaning to each figure it cannot source.

A proposed consent order is not a finished rule. It typically carries a public-comment window before the Commission votes to make it final, which means the caps are a commitment on the table rather than an obligation in force [1].

CVS Caremark's position, consistent with what large PBMs argue, is that rebate negotiation lowers overall drug spending for the plans they serve. The FTC's order does not dispute that PBMs negotiate discounts; it targets where the discount lands, moving it from the plan's ledger to the patient's receipt. Both claims can hold at once: rebates can lower a plan's aggregate cost and still leave the individual insulin user paying a list-price-linked amount at the counter.

For a diabetic on a Caremark plan, a hard $25, $50 or $75 ceiling is the difference between a predictable fill and a variable bill that has run into the hundreds for some list-price insulins. What the order does not do is lower insulin list prices, and it reaches only the plans Caremark administers, not the many plans its competitors run. A public-comment period and a final Commission vote still stand between the proposal and any patient's lower copay.